Market closedNon-fractional
Sangamo Therapeutics/SGMO
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Sangamo Therapeutics
Sangamo Therapeutics Inc is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. Its pipeline products include the Priority Neurology Pipeline offers Chronic Neuropathic Pain, Prion Disease, and Neurology; Partnered Programs offer Hemophilia A, Oncology, ALS/FTD, and Huntington's Disease; and Other Pipelines include Fabry Disease, Renal Transplant, Inflammatory Bowel Disease, and Multiple Sclerosis.
Ticker
SGMO
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
Richmond, United States
Employees
405
Website
www.sangamo.com
SGMO Metrics
BasicAdvanced
$67M
Market cap
-
P/E ratio
-$1.85
EPS
1.40
Beta
-
Dividend rate
Price and volume
Market cap
$67M
Beta
1.4
Financial strength
Current ratio
1.706
Quick ratio
1.369
Long term debt to equity
54.354
Total debt to equity
54.354
Management effectiveness
Return on assets (TTM)
-49.47%
Return on equity (TTM)
-167.24%
Valuation
Price to revenue (TTM)
3.05
Price to book
1.16
Price to tangible book (TTM)
1.16
Price to free cash flow (TTM)
-0.262
Growth
Revenue change (TTM)
-92.22%
Earnings per share change (TTM)
129.68%
3-year revenue growth
-47.74%
3-year earnings per share growth
28.17%
What the Analysts think about SGMO
Analyst Ratings
Majority rating from 9 analysts.
SGMO Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$400K
-80.00%
Net income
-$49M
-18.60%
Profit margin
-12,250.00%
306.98%
SGMO Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.66
-$0.59
-$0.34
-$0.27
-
Expected
-$0.34
-$0.32
-$0.26
-$0.21
-$0.15
Surprise
92.73%
84.37%
32.70%
26.32%
-
SGMO News
AllArticlesVideos
Sangamo Therapeutics Announces First Quarter 2024 Conference Call and Webcast
Business Wire·2 months ago
Sangamo Therapeutics to Present Neurology-Focused Pre-Clinical Data From Its Epigenetic Regulation, Capsid Delivery and Genome Engineering Platforms at the 27th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
Business Wire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Sangamo Therapeutics stock?
Sangamo Therapeutics (SGMO) has a market cap of $67M as of July 06, 2024.
What is the P/E ratio for Sangamo Therapeutics stock?
The price to earnings (P/E) ratio for Sangamo Therapeutics (SGMO) stock is 0 as of July 06, 2024.
Does Sangamo Therapeutics stock pay dividends?
No, Sangamo Therapeutics (SGMO) stock does not pay dividends to its shareholders as of July 06, 2024.
When is the next Sangamo Therapeutics dividend payment date?
Sangamo Therapeutics (SGMO) stock does not pay dividends to its shareholders.
What is the beta indicator for Sangamo Therapeutics?
Sangamo Therapeutics (SGMO) has a beta rating of 1.4. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
Buy or sell Sangamo Therapeutics stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.